Clay Siegall, the co-founder, president, CEO and board chairman of Seattle Genetics, is on a quest to change cancer therapy. The company created a number of innovative advancements that have led to a tripling of the value of their stock in the last 5 years. Dr. Siegall became involved in biomedical studies and cancer research because he is passionate about improving cancer patients’ lives and alleviating their suffering. Since co-founding the company in 1998, Seattle Genetics has made great cancer research advancements and created groundbreaking, very effective, cancer therapies.
Since graduating from George Washington University with a Ph.D. in Genetics, Dr. Siegall has worked at Bristol-Myers Squibb Pharmaceutical Research Institute as a principal scientist and senior research investigator. He then joined the National Cancer Institute as a biotechnology and staff fellow before launching Seattle Genetics. Dr. Clay Siegall is committed to creating and implementing cutting-edge research developments. Under his leadership Seattle Genetics has developed ADCETRIS®, the first antibody-drug conjugate to win FDA approval. This ADC is having a global impact.
Cancer patients in 60 countries are now treated with ADCETRIS®. Dr. Siegall’s dedication and perseverance has helped make this and other new cancer therapies a priority in the medical community. He has reached out to public and private sources to raise over $1.2 billion to fund Seattle Genetics’ research and development program. This has enabled them to create innovative technologies to advance cancer treatment. Dr. Clay Siegall’s visionary leadership and scientific acumen has taken the scientific advancements of Seattle Genetics to new heights.
The significant contributions Dr. Siegall has made to the medical and scientific communities have earned him many awards and accolades. Ernst & Young voted him Pacific Northwest Entrepreneurs of the Year in 2012. In 2013, his alma mater, The University of Maryland, named him Alumnus of the Year for Computer, Math and Natural Sciences. And he continues to work towards new cancer treatment discoveries and research methods. In addition to holding 15 science-related patents, Dr. Siegall has published over 70 scientific articles and is on three scientific journals’ editorial boards so he can share his advanced knowledge.